GlassScriptPhysician profile
Albert D Min
NPI 1396720256
$276,932.16
in general payments reported to CMS, 2019-2025
12 companies · $59K in 2025
The $59K reported for 2025 was more than what 87% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $26K · 2021: $33K · 2022: $25K · 2023: $28K · 2024: $41K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $103K · Travel and Lodging: $12K · Consulting Fee: $6,970 · Food and Beverage: $5,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $103,396.50 |
| Travel and Lodging | $12,225.23 |
| Consulting Fee | $6,970.00 |
| Food and Beverage | $5,418.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $170,060.05 | 2019-2025 | Epclusa, Vemlidy |
| Madrigal Pharmaceuticals | $47,106.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $40,065.20 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $11,939.14 | 2019-2021 | |
| Glaxosmithkline, LLC. | $3,200.00 | 2025 | |
| Novo Nordisk INC | $2,712.50 | 2023 | |
| Eisai INC. | $1,620.00 | 2020 | |
| Janssen Biotech, INC. | $99.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.38 | 2019 | |
| Merck Sharp & Dohme LLC | $41.68 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $27.32 | 2024 | Iqirvo |
| Allergan, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Min listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.